A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research Consortium BTCRC-LYM20-463

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Rituximab (Primary) ; Tazemetostat (Primary)
Indications Follicular lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

21 Oct 2024 Planned End Date changed from 1 May 2025 to 1 May 2027.
21 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 1 May 2026.
19 Sep 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight